US2007015775A1PendingUtilityA1

Heterocyclic compounds

63
Individually held — no corporate assignee on recordPriority: Jan 12, 1998Filed: Sep 19, 2006Published: Jan 18, 2007
Est. expiryJan 12, 2018(expired)· nominal 20-yr term from priority
Inventors:Malcom Clive CarterGeorge Stuart CockerillStephen Barry GuntripKaren Elizabeth LackeyKathryn Jane Smith
A61P 43/00A61P 9/10A61P 37/00A61P 9/00A61P 29/00A61P 35/00A61P 3/10A61P 31/00A61P 17/00A61P 17/06C07D 239/94C07D 417/04A61K 31/517C07D 405/14C07D 417/14C07D 411/04C07D 471/04C07D 405/04A61K 31/519
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II)  wherein L and L′ are suitable leaving groups, with a compound of formula (III) UNH 2   (III)  to prepare a compound of formula (IV)  and subsequently (b) substituting the group R 1 by replacement of the leaving group L′.

Claims

exact text as granted — not AI-modified
1 . A method of inhibiting EGFR in a mammal subject, comprising administering to said mammal an effective amount of a compound of the formula:  
       
         
           
           
               
               
           
         
       
       or salts or solvates thereof.  
     
     
         2 . A method as claimed in  claim 1 , wherein the mammal is a human.  
     
     
         3 . A method as claimed in  claim 1 , wherein the mammal is a human suffering from a cancer exhibiting aberrant EGFR activity.  
     
     
         4 . A method of inhibiting c-erbB-2 in a mammal subject, comprising administering to said mammal an effective amount of a compound of the formula:  
       
         
           
           
               
               
           
         
       
       or salts or solvates thereof.  
     
     
         5 . A method as claimed in  claim 4 , wherein the mammal is a human.  
     
     
         6 . A method as claimed in  claim 4 , wherein the mammal is a human suffering from a cancer exhibiting aberrant c-erbB-2 activity.  
     
     
         7 . A method of inhibiting EGFR and c-erbB-2 in a mammal subject, comprising administering to said mammal an effective amount of a compound of the formula:  
       
         
           
           
               
               
           
         
       
       or salts or solvates thereof.  
     
     
         8 . A method as claimed in  claim 7 , wherein the mammal is a human.  
     
     
         9 . A method as claimed in  claim 7 , wherein the mammal is a human suffering from a cancer exhibiting aberrant EGFR and c-erbB-2 activity.

Join the waitlist — get patent alerts

Track US2007015775A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.